Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of “Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $34.00.

Several research firms have issued reports on RCUS. HC Wainwright reiterated a “neutral” rating and set a $20.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a report on Thursday, October 3rd. Finally, Barclays boosted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, October 25th.

Insider Buying and Selling

In related news, CFO Robert C. Goeltz II sold 3,594 shares of Arcus Biosciences stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RCUS. R Squared Ltd bought a new stake in shares of Arcus Biosciences during the fourth quarter worth approximately $26,000. Point72 Hong Kong Ltd acquired a new stake in Arcus Biosciences during the 3rd quarter worth $47,000. Point72 DIFC Ltd bought a new stake in shares of Arcus Biosciences during the 2nd quarter valued at $83,000. Quest Partners LLC lifted its stake in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares during the period. Finally, Intech Investment Management LLC bought a new position in shares of Arcus Biosciences in the 3rd quarter worth $244,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock opened at $13.42 on Tuesday. Arcus Biosciences has a twelve month low of $12.88 and a twelve month high of $20.31. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The firm has a market cap of $1.23 billion, a P/E ratio of -4.26 and a beta of 0.87. The firm’s 50-day simple moving average is $15.28 and its 200-day simple moving average is $15.91.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.06. The company had revenue of $48.00 million for the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company’s revenue was up 50.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.94) EPS. As a group, research analysts expect that Arcus Biosciences will post -3.2 EPS for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.